Reprint

Brain Injury and Neurodegeneration: Molecular, Functional, and Translational Approach

Edited by
August 2023
428 pages
  • ISBN978-3-0365-8384-6 (Hardback)
  • ISBN978-3-0365-8385-3 (PDF)

This book is a reprint of the Special Issue Brain Injury and Neurodegeneration: Molecular, Functional, and Translational Approach that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

With the advancements in the medical and scientific fields, the global community has acquired a comprehensive understanding about brain insults and pathologies. In addition, new findings and discoveries are being made globally every day, which keep our curiosity high and drive a knowledge gain. Any brain insult or pathology is multifactorial, including a cascade of inflammation, necrotic, and apoptotic pathways; can be influenced by genetic or environmental factors; and may lead to chronic neurodegeneration or disabilities.  This Special Issue, entitled “Brain Injury and Neurodegeneration: Molecular, Functional, and Translational Approach”, has addressed various important aspects of brain injury and neurodegeneration, such as TBI, cerebral hypoxia, epilepsy, AD, and SARS-CoV-2-mediated brain damage. It received appreciable global response, and published 18 peer-reviewed articles, including 10 research articles and 8 reviews. Briefly, it explores the recent coronavirus infection-mediated cerebral damage; discusses the mechanism of TBI, ischemia, hypoxia, and epilepsy; talks about neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and CONDCA; and, finally, reviews the translational values of phytochemicals in brain pathologies. In conclusion, this Special Issue provides a unique review on brain injury and neurodegeneration, and will be a good tool in enhancing knowledge in terms of brain disease-related pathology, mechanisms, and translational approach.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
neurodegenerative diseases; phytochemicals; natural products; neuroprotection; neurotrauma; neuroinflammation; excitotoxicity; oxidative stress; apoptosis; edema; brain injury; therapeutic strategies; 18F-FDG PET; anosmia; COVID-19; SARS-CoV-2; olfactory dysfunction; anti-convulsants; anti-epileptic drugs; drug targets; epileptogenesis; non-communicable disease; seizures; transcriptional modifications; pseudo-resistance; ischemia; FABP3; FABP5; FABP7; mPGES-1; PGE2; treadmill exercise; Parkinson’s disease; neural mitochondrial functions; amyloid beta; Alzheimer’s disease; inflammation; gene regulation; organelle dysfunction; AGTPBP1; CCP1; CONDCA; neurodegeneration; NNA1; pcd; microglia; neuroinflammation; chronic alcoholism; HHV-6; Substantia Nigra; ischemic stroke; epigenetics; histone deacetylase; histone deacetylase inhibitor; mechanical stimulations; traumatic brain injury (TBI); stretching; neurons; GSK-3β; p-Tau; extracellular matrix; icariin; icaritin; ischemic stroke; middle cerebral artery occlusion; traumatic brain injury; blunt-force TBI; post-traumatic seizures; zebrafish; sonic hedgehog signaling; purmorphamine; mild traumatic brain injury; microRNA; exomiRNA; exosome; TBI; tRNA; miRNA; isomiR; neuroinflammation; RNAseq; neurotrauma; oxidative stress; neurodegeneration; neuroinflammation; moderate traumatic brain injury; Alzheimer’s disease; reactive oxygen species; oxidative stress; cognitive impairment; mitochondria; hypoxia; ischemia; neuraxis; hypoxic-ischemic injuries; neural ischemia; neural tissue hypoxic injuries; neuro-recovery; neurorehabilitation; n/a